Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Jan 17, 2020

SELL
$60.18 - $154.77 $183,007 - $470,655
-3,041 Closed
0 $0
Q3 2019

Oct 18, 2019

BUY
$140.29 - $189.96 $107,883 - $146,079
769 Added 33.85%
3,041 $427,000
Q2 2018

Jul 24, 2018

BUY
$140.36 - $175.76 $34,949 - $43,764
249 Added 12.31%
2,272 $356,000
Q1 2018

May 03, 2018

BUY
$152.15 - $192.33 $11,259 - $14,232
74 Added 3.8%
2,023 $326,000
Q4 2017

Feb 14, 2018

BUY
$60.72 - $167.34 $118,343 - $326,145
1,949
1,949 $321,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $284M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Zeke Capital Advisors, LLC Portfolio

Follow Zeke Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zeke Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Zeke Capital Advisors, LLC with notifications on news.